Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results